封面
市場調查報告書
商品編碼
1137008

骨關節炎治療藥市場:各藥物類別,各給藥途徑,各疾病類型,各流通管道,各地區- 規模,佔有率,展望,機會分析,2022年~2030年

Osteoarthritis Drugs Market, by Drug Class, by Route of Administration, by Disease Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: | 出版商: Coherent Market Insights | 英文 231 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場動態

市場的主要參與者專注於收購等有機增長戰略,預計這將在預測期內推動全球骨關節炎治療市場的增長。

本調查的主要特徵

  • 本報告提供以2021年為基準年的預測期間(2022-2030 年)之全球骨關節炎治療藥市場的市場規模和復合年增長率(CAGR %)相關的詳細分析。
  • 並闡明不同部門市場的潛在收入機會,說明該市場具有魅力的投資主張矩陣。
  • 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
  • 並基於企業亮點,各類型投資組合、主要焦點、財務業績和市場策略等參數,介紹全球骨關節炎治療藥市場的主要參與者之企業簡介。
  • 藉由該報告提供的洞察,將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
  • 全球骨關節炎治療藥市場報告配合該行業的各種利益相關者,包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以透過全球骨關節炎治療藥市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 前提條件
  • 簡稱的說明

第2章 市場展望

  • 報告內容
  • 市場定義和範圍
  • 摘要整理
    • 市場明細:各藥物類別
    • 市場明細:各給藥途徑
    • 市場明細,各疾病類型
    • 市場明細:各流通管道
    • 市場明細,各地區
  • 連貫機遇地圖(COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 開發平台分析
  • 保險償付方案
  • 流行病學
  • PEST分析
  • 法律規章情景
  • 新產品的上市
  • 共同研究及契約
  • 市場趨勢

第4章 骨關節炎治療藥的全球市場-冠狀病毒(COVID-19)疫情的影響

  • 整體影響
  • COVID-19市場的影響

第5章 骨關節炎治療藥的全球市場,各藥物類別,2017年~2030年

  • 止痛藥
  • 非類固醇消炎劑
  • 皮質類固醇
  • 玻尿酸
  • 階段III醫藥品

第6章 骨關節炎治療藥的全球市場(各給藥途徑):2017年~2030年

  • 口服劑
  • 非口服劑
  • 局部給藥

第7章 骨關節炎治療藥的全球市場,各疾病類型,2017年~2030年

  • 腳踝的骨關節炎
  • 變形性髖關節症
  • 變形性膝關節症
  • 變形性肩關節症
  • 其他(脊椎骨關節炎,頸椎骨關節炎)

第8章 骨關節炎治療藥的全球市場(各流通管道):2017年~2030年

  • 醫院內藥局
  • 零售藥局
  • 線上藥局

第9章 骨關節炎治療藥的全球市場:各地區,2017年~2030年

  • 北美
  • 美國
  • 加拿大
  • 南美
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他的南美地區
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 中東地區
  • GCC
  • 以色列
  • 其他的中東地區
  • 非洲
  • 北非
  • 中非
  • 南非

第10章 競爭情形

  • 熱圖分析
  • 企業簡介
    • Pfizer, Inc.
    • Abbott
    • Eli Lilly and Company
    • ABIOGEN PHARMA S.p.A
    • Horizon Therapeutics plc
    • Ferring B.V.
    • Merck Sharp & Dohme Corp.
    • Medivir
    • Bioventus
    • Sanofi
    • Regeneron
    • GlaxoSmithKline Plc.
    • Johnson & Johnson Private Limited
    • Bayer AG
    • Novartis AG
    • Ferring B.V.
    • Pacira Pharmaceuticals, Inc
    • Zimmer Biomet
    • OrthogenRx, Inc.
    • PHARMED LTD

第11章 章節

  • 參考文獻
  • 調查手法的介紹
  • 關於出版社
簡介目錄
Product Code: CMI2580

Osteoporosis is a systemic disorder characterized by decreased bone mass and microarchitectural deterioration of bone tissue, leading to bone fragility and increased susceptibility to fractures of the hip, spine, and wrist. Due to its important prevalence worldwide, osteoporosis is considered a serious public health concern associated with disability and pain. The pathophysiology of osteoporosis is an imbalance between bone resorption and bone formation. In osteoporosis, bone resorption takes place to a greater extent than bone formation, so a negative balance occurs with a net loss of bone and an accompanying increasing risk of fractures, resulting in deformity and chronic pain. Nociceptive pain is considered to be chronic when it has been present for at least 3 months.

  • The imbalance between bone formation and bone resorption might occur as a result of one or a combination of the following factors:
  • Increased bone resorption within a remodeling unit.
  • Decreased bone formation within a remodeling unit (incomplete coupling)

Market Dynamics

Key players in the market are focused on organic growth strategies such as acquisitions, which is expected to drive the global osteoarthritis drugs market growth over the forecast period. For instance, on August 15, 2022, Gurnet Point Capital, an investment service company and Patient Square Capital, a healthcare investment company, announced the completion of their acquisition of Radius Health, Inc., a Biotechnology Company. Radius' lead product, TYMLOS (abaloparatide) was launched in the U.S. in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. This acquisition will help the company in further expansion in the osteoarthritis drugs market over the forecast period.

However, use of Non-steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and naproxen in pain management of osteoarthritis can cause cardiovascular diseases, which in turn is expected to hinder the market growth. For instance, in June 2018, the European League against Rheumatism (EULAR) stated the risk of cardiovascular diseases with the regular use of NSAIDs in the treatment of osteoarthritis pain.

Key features of the study:

  • This report provides an in-depth analysis of the global osteoarthritis drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 - 2030, considering 2021 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global osteoarthritis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Pfizer, Inc., Abbott, Eli Lilly and Company, ABIOGEN PHARMA S.p.A, Horizon Therapeutics plc, Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Sanofi, Regeneron, GlaxoSmithKline Plc., Johnson & Johnson Private Limited, Bayer AG, Novartis AG, Ferring B.V., Pacira Pharmaceuticals, Inc, Zimmer Biomet, OrthogenRx, Inc. and PHARMED LTD.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future drug launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global osteoarthritis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for drug market, research and consulting firms, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoarthritis drugs market

Detailed Segmentation:

  • Global Osteoarthritis Drugs Market, By Drug Class:
    • Analgesics
    • Non-steroidal Anti-Inflammatory Drugs
    • Corticosteroids
    • Hyaluronic Acid
    • Phase III Drugs
  • Global Osteoarthritis Drugs Market, By Route of Administration:
    • Oral
    • Parenteral
    • Topical
  • Global Osteoarthritis Drugs Market, By Disease Type:
    • Ankle Osteoarthritis
    • Hip Osteoarthritis
    • Knee Osteoarthritis
    • Shoulder Osteoarthritis
    • Others (Spinal Osteoarthritis and Cervical Osteoarthritis)
  • Global Osteoarthritis Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Osteoarthritis Drugs Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Pfizer Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Abbott
    • Eli Lilly and Company
    • ABIOGEN PHARMA S.p.A
    • Horizon Therapeutics plc
    • Ferring B.V.
    • Merck Sharp & Dohme Corp.
    • Medivir
    • Bioventus
    • Sanofi
    • Regeneron
    • GlaxoSmithKline Plc.
    • Johnson & Johnson Private Limited
    • Bayer AG
    • Novartis AG
    • Ferring B.V.
    • Pacira Pharmaceuticals, Inc
    • Zimmer Biomet
    • OrthogenRx, Inc.
    • PHARMED LTD

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
  • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Route of Administration
    • Market Snippet, By Disease Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Reimbursement Scenario
  • Epidemiology
  • Pest Analysis
  • Regulatory Scenario
  • New Product Launches
  • Collaborations and Agreements
  • Market Trends

4. Global Osteoarthritis Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

  • Overall Impact
  • COVID-19 Impact on the market

5. Global Osteoarthritis Drugs Market, By Drug Class, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Analgesics
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Nonsteroidal Anti-Inflammatory Drugs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Corticosteroids
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Hyaluronic Acid
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Phase III Drugs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Osteoarthritis Drugs Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017- 2030
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Parenteral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Topical
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Osteoarthritis Drugs Market, By Disease Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017- 2030
    • Segment Trends
  • Ankle Osteoarthritis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Hip Osteoarthritis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Knee Osteoarthritis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Shoulder Osteoarthritis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others (Spinal Osteoarthritis and Cervical Osteoarthritis)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Osteoarthritis Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million )

9. Global Osteoarthritis Drugs Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Heat Map Analysis
  • Company Profile
    • Pfizer, Inc.
  • Company Highlights
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Market Strategies
    • Abbott
    • Eli Lilly and Company
    • ABIOGEN PHARMA S.p.A
    • Horizon Therapeutics plc
    • Ferring B.V.
    • Merck Sharp & Dohme Corp.
    • Medivir
    • Bioventus
    • Sanofi
    • Regeneron
    • GlaxoSmithKline Plc.
    • Johnson & Johnson Private Limited
    • Bayer AG
    • Novartis AG
    • Ferring B.V.
    • Pacira Pharmaceuticals, Inc
    • Zimmer Biomet
    • OrthogenRx, Inc.
    • PHARMED LTD
  • Analyst Views

11. Section

  • References
  • Research Methodology
  • About Us